The Complete GLP-1 Guide for Men.

GLP-1 receptor agonists have produced the most significant advance in weight management pharmacology in decades. Semaglutide (Wegovy) demonstrated 14.9% mean body weight loss. Tirzepatide (Zepbound) pushed that to 22.5%. Retatrutide hit 24.2% in Phase 2. These are not marginal improvements—they represent a paradigm shift in how we approach weight loss.

But for men, especially men who train, the conversation is more nuanced than just weight loss. The male-specific concerns around GLP-1 drugs center on three issues: lean mass preservation, hormonal impacts, and performance effects. This guide addresses all three.

GLP-1 (glucagon-like peptide-1) is a natural hormone released by intestinal L-cells after eating. It signals satiety to the brain, slows gastric emptying, and enhances insulin secretion. Native GLP-1 is degraded by DPP-4 enzyme within minutes.

Semaglutide extends GLP-1 activity to ~7 days through structural modifications. The result is sustained appetite suppression that reduces caloric intake by 25-35% without conscious willpower. Tirzepatide adds GIP receptor agonism for enhanced insulin sensitivity and potentially greater central appetite suppression. Retatrutide adds glucagon receptor agonism, which increases energy expenditure and hepatic fat oxidation.

For a detailed comparison, see the GLP-1 Showdown comparison.

This is the elephant in the room for men who train. GLP-1-mediated weight loss is not purely fat loss. In the STEP 1 trial, approximately 39% of weight lost on semaglutide was lean mass. For a man losing 30 pounds, that could mean ~12 pounds of muscle loss—devastating for someone who spent years building it.

Mitigation strategies are critical:

Resistance training: Non-negotiable. Studies show that resistance training during GLP-1 therapy significantly reduces lean mass loss. Train at least 3-4 times per week with progressive overload.

Protein intake: Target 1.6-2.2g per kg of bodyweight daily. This is challenging when appetite is suppressed, so protein prioritization in meal planning becomes essential.

GH optimization: Some researchers combine GLP-1 drugs with GH secretagogues like CJC-1295/Ipamorelin or tesamorelin to support lean mass preservation. The Cut Stack protocol (Semaglutide + Tesamorelin + 5-Amino-1MQ) includes tesamorelin specifically for this purpose.

Rate of loss: Aggressive weight loss increases muscle loss risk. A moderate deficit (500-750 calories) preserves more lean mass than an extreme deficit, even if total weight loss is slower.

Weight loss itself tends to improve testosterone levels in overweight men, as adipose tissue converts testosterone to estrogen via aromatase. However, rapid weight loss and severe caloric restriction can temporarily suppress testosterone.

The data on GLP-1 drugs and testosterone is mixed. Some studies show testosterone increases concurrent with fat loss (expected from reduced aromatization). Others show no significant hormonal changes beyond what weight loss alone would predict. There is no evidence that GLP-1 drugs directly suppress testosterone production.

For men concerned about hormonal optimization during GLP-1 therapy, monitoring testosterone levels every 8-12 weeks provides data to guide decisions. If testosterone drops despite fat loss, this likely reflects excessive caloric restriction rather than a drug-specific effect.

For men prioritizing evidence and safety data: semaglutide has years of post-marketing surveillance, proven cardiovascular outcomes (20% MACE reduction in SELECT trial), and an oral formulation option.

For men prioritizing maximum weight loss from an approved compound: tirzepatide produces greater average weight loss (22.5% vs 14.9%) with a similar side effect profile.

For men willing to use investigational compounds: retatrutide has shown the highest weight loss (24.2%) and remarkable liver fat clearance, but Phase 3 data and long-term safety information are still forthcoming.

All three require dose escalation over 16-20 weeks to minimize GI side effects. Patience during titration is essential—jumping to full dose guarantees misery.

GLP-1 drugs are genuinely effective for weight loss, but men who train must actively mitigate lean mass loss through resistance training, high protein intake, and potentially GH-supporting compounds. Semaglutide has the strongest overall evidence base. Tirzepatide produces greater weight loss. Retatrutide is the highest-ceiling investigational option. The muscle preservation strategies are not optional—they are the difference between losing fat and losing the physique you built.